REFERENCES

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2020 [article online], Available from https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes- statistics-report.pdf:https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics- report.pdf

2.

3. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S125-S150.

4. American Diabetes Association. 14. Management of diabetes in pregnancy: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S200-S210.

5. American Diabetes Association. 3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S34-S39.

6. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S73-S84.

7. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract. 2018;24:91-120.

8. Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEngl J Med. 1993;329:977-986.

9. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. NEngl J Med. 2008;359:1577-1589.

10. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data Interpretation: recommendations from the international consensus on time in range.

2019;42:1593-1603.

11. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. NEngl J Med. 2008;358:2545-2559.

12. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. NEngl J Med 2009;360:129-139.

13. ACCORD Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med. 2008;358:2560-2572.

14. American Diabetes Association. 7. Diabetes technology: standards of medical Care in diabetes- 2021. Diabetes Care. 2021;44:S85-S99.

15. American Diabetes Association. 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S53-S72.

16. Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12:222-232.

17. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S211-S220.

18. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017;2017:33:doi:10.1002/dmrr.2924

19. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev. 2016;2016:CD011281.

20. Haas NL, Gianchandani RY, Gunnerson KJ, et al. The two-bag method for Treatment of diabetic ketoacidosis in adults. J Emerg Med. 2018;54:593-599.

21. Dhatariya KK, Vellanki P. Treatment of diabetic ketoacidosis (DKA)#8725;Hyperglycemic hyperosmolar state (HHS): novel advances in the management of hyperglycemic crises (UK versus USA). Curr Diab Rep. 2017;17:33.

22. Diabetes Canada Clinical Practice Guidelines Expert Committee; McGibbon A, Adams L, et al. Glycemic management in adults with type 1 diabetes. Can J Diabetes. 2018;42(suppl 1):S80-S87.

23. Heise T, Linnebjerg H, Coutant D, et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study. Diabetes Obes Metab. 2020;22:1789-1798

24. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787- 794.

25. Lawrence JM, Divers J, Isom S, et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA 2021;326:717-727.

26. Mizukami H, Kudoh K. Diversity of pathophysiology in type 2 diabetes shown by islet pathology. J Diabetes Investig. Published online 2021.doi:10.1111/jdi.13679

27. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S111-S124.

28. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653-662.

29. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-39.

30. Jampol LM, Glassman AR, Sun J. Evaluation and care of patients with diabetic retinopathy. N Engl

J Med. 2020;382:1629-1637.

31. American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S151-S167.

32. Bakris GL, Agarwal R, Anker SD, et al.

33. Vinik AI. Clinical practice: diabetic sensory and motor neuropathy. NEngl J Med. 2016;374:1455- 1464

34. Rawshani A, Rawshani A, Franzen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. NEngl J Med. 2017;376:1407-1418.

35. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes—the DIAD study: a randomized controlled trial. JAMA. 2009;301:1547-1555.

36. Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120:S37-S47.

37. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461-2498.

38. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society. Diabetes Care. 2013;36:1384-1395.